Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma—a tightrope walk
ObjectiveMechanistic/mammalian target of rapamycin (mTOR) inhibitors have been used successfully to reduce the size of cardiac rhabdomyomas. However, the number of published cases is small and thus there is no consensus about therapeutic approaches, especially regarding dosing regimens and safety pr...
Saved in:
| Main Authors: | Nadine Muschel, Michaela Höck, Elke Griesmaier, Samira Abdel Azim, Elisabeth Ralser, Christina Schreiner, Elisabeth Schermer, Ursula Kiechl-Kohlendorfer, Irene Mutz-Dehbalaie, Miriam Michel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1649341/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transplacental sirolimus: a new treatment strategy for life-threatening fetal cardiac rhabdomyomas—a case report
by: Kaname Uno, et al.
Published: (2025-06-01) -
Infantile Kaposiform hemangioendothelioma in a female patient complicated with severe obstructed jaundice: a case report
by: Eiichiro Watanabe, et al.
Published: (2022-12-01) -
Effectiveness and safety of topical sirolimus in children with angiofibromas and tuberous sclerosis complex
by: Andrea Fernández de Lara-Arrieta, et al.
Published: (2025-04-01) -
Rapamycin for longevity: the pros, the cons, and future perspectives
by: Kelley M. Roark, et al.
Published: (2025-06-01) -
Challenges and treatment outcome of patients with Kaposiform hemangioendothelioma: a retrospective single center experience
by: Nihal Hussien Aly, et al.
Published: (2025-05-01)